Premas Life Sciences-IncellDx Sign Distribution Agreement After Successful Study at AIIMS
New Delhi: Premas Life Sciences Pvt., Ltd. and IncellDx, Inc. announced today they have signed an exclusive distribution agreement. The commercial partnership brings the power of cell by cell multiplex diagnostics for solid tumors carcinomas that can now be analyzed for molecular and protein biomarkers by flow cytometry. Included in the deal are: IncellDx's patented single-cell assays for quantifying PD-L1 on tumor cells and immune cell subtypes; patented single-cell assay for HPV E6/E7 mRNA detection in cervical samples; and, its incellPREP single-cell preparation kit for solid tissues including tumors. Researchers at AIIMS, New Delhi have completed a successful study utilizing IncellDx's next generation (3Dx) investigational molecular assay which quantifies E6, E7 mRNA overexpression in single cells simultaneously with the measurement of cell cycle and cell proliferation, the hallmark of progressive disease.
Praveen Gupta,Managing Director of Premas Life Sciences commented: “India’s moleculardiagnostics market needs a refreshing change with IncellDx’s OncoTect assaysthat offer revolutionary single cell proteomic and genomics marker baseddiagnostic and more importantly a prognostic solutions for early detection andstaging for cancer patients with more targeted immuno-onco therapies.India's cancer burden is increasing and IncellDx offers a perfect path forhighly effective companion diagnostic not just to researchers but also topatients. We are indeed delighted to be a part of this change.”
Bruce Patterson MD,CEO of IncellDx commented: "We are excited about this opportunity to bringmolecular testing to the flow cytometry field in a region of the world with agreat appetite for innovation in the molecular space. The hallmark of cancerresearch is the quantification of oncogenes and the downstream effects on cellcycle which we have incorporated into a clinical assay. However, as cytologysamples contain a heterogeneous mixture of normal and abnormal cells, it iscritical that we are able to carry out quantification at the single celllevel."
IncellDx is amolecular diagnostics company dedicated to revolutionizing healthcare one cellat a time. By combining molecular diagnostics with high throughput cellularanalysis, the company's focus is on critical life threatening diseases in theareas of cancer, specifically lung, cervical, head and neck, bladder,cancers. http://incelldx.com/